Infinity Pharmaceuticals, Inc. announced that, in the fourth quarter of 2013, it expects to initiate a Phase 3 trial of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
This randomized study is designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg twice daily (BID) compared to ofatumumab in approximately 300 relapsed or refractory patients.
Clinical trial results & reviews of new treatments for CLL written in easy to understand terms Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLLDiptheria Immunotoxin Effectively Targets B-Cell Malignancies - Phase 1 trial of DT2219Analysing and Resequencing Gene Panels from the UK CLL4 trial (1999-2004) is helping patients today.FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
